Zealand Pharma appears to have taken a small step forward with a candidate that targets both GLP-1 and GLP-2, an approach ...

Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the ...

No­vo Nordisk’s semaglu­tide hit its sec­ondary end­points in the Phase 3 FLOW tri­al, demon­strat­ing a re­duc­tion in the ...

As Johnson & Johnson attempts to settle tens of thousands of talc lawsuits, a group of five plaintiffs filed new litigation ...

When Pfizer laid out the ambitious vision for its new oncology division in February, it announced that it was taking the ...

Nuvation Bio showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol ...

The European Commission on Thursday finalized rules on how it pools expertise from across the EU to assess the effectiveness ...

Hornet Therapeutics is on a mission to prevent and treat conditions related to the Epstein-Barr virus (EBV) with the help of ...

Nimbus Therapeutics closed one of the biggest single-drug deals in biotech, selling its TYK2 inhibitor to Takeda for $4 ...

Abstracts for the American Society of Clinical Oncology are out, with new data from Pfizer's ADC, Nimbus Therapeutics' immuno ...

SR One, a life sciences venture capital firm that years ago split from GSK, has raised more than $200 million for a growth ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...